+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group



Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group



Aids 13(7): 851-858



This double-blind study evaluated treatment with zalcitabine-zidovudine, saquinavir-zidovudine, or saquinavir-zalcitabine-zidovudine on the health-related quality of life of HIV-infected adults with CD4 cell counts between 50 and 350 cells/mm3. Nine hundred and ninety-three HIV-infected male or female quality of life substudy patients aged 18 years or older, with CD4 cell counts between 50 and 350 cells/mm3 naïve to antiretroviral therapy or with less than 16 weeks of zidovudine therapy, were randomly assigned to one of three daily regimens: zalcitabine 0.75 mg and zidovudine 200 mg every 8 h (ddC/ZDV); saquinavir 600 mg and zidovudine 200 mg every 8 h (SQV/ZDV); or saquinavir 600 mg, zalcitabine 0.75 mg and zidovudine 200 mg every 8 h (SQV/ddC/ZDV). The health-related quality of life was measured using the Medical Outcome Study HIV (MOS-HIV) Health Survey subscale and physical and mental health summary scores, and a global visual analogue scale (VAS) score. The primary health-related quality of life endpoints were the MOS-HIV physical and mental health summary scores. After 24 weeks of treatment, no statistically significant differences were observed between the three treatment groups on physical health and mental health summary scores (global test P = 0.118). After 48 weeks of treatment, statistically significant differences among the groups were observed for physical health and mental health summary scores (global test P = 0.020); no change in physical health summary scores from the baseline were seen in the triple combination therapy, whereas the ddC/ZDV combination therapy group showed decreases from baseline in physical health summary scores (P = 0.008). Six of the 10 individual MOS-HIV subscale scores and the VAS scores showed results consistent with the physical health summary endpoints after 48 weeks of therapy. No statistically significant differences in baseline to 48 week changes in MOS-HIV subscale or summary scores were seen between the ddC/ZDV and SQV/ZDV groups (P > 0.05). Patients on triple combination therapy maintained their quality of life over 48 weeks compared with significant decreases in the quality of life for ddC/ZDV combination therapy.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047144381

Download citation: RISBibTeXText

PMID: 10357386


Related references

Resistance Mutations to Zidovudine and Saquinavir in Patients Receiving Zidovudine Plus Saquinavir or Zidovudine and Zalcitabine Plus Saquinavir in Aids Clinical Trials Group 229. The Journal of Infectious Diseases 179(1): 249-253, 1999

Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. Journal of Infectious Diseases 179(1): 249-253, 1999

Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3. Antiviral Therapy 4(1): 35-44, 1999

Saquinavir + zalcitabine vs saquinavir or zalcitabine monotherapy in HIV-infected patients discontinuing or intolerant to zidovudine Results of a randomized, double blind trial. AIDS (London) 10(Suppl. 2): S17, 1996

Effects of combination therapy with saquinavir, zidovudine and zalcitabine on quality of life. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS [Author] Eleventh International Conference on AIDS, Vol One One world: One hope : 239, 1996

Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrobial Agents and ChemoTherapy 41(11): 2428-2432, 1997

Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrobial Agents and ChemoTherapy 41(11): 2433-2438, 1997

Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee. Antiviral Therapy 2(4): 229-236, 1997

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus zalcitabine is preferred to zidovudine plus didanosine. Reviews in Medical Virology 4(1): 5-8, 1994

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus didanosine is preferred to zidovudine plus zalcitabine. Reviews in Medical Virology 4(1): 9-12, 1994

A comparative study of saquinavir , and zidovudine vs ZDV and zalcitabine vs SAQ, ZDV, and ddC. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 34: 60, 1994

Extended treatment with saquinavir , zidovudine , and zalcitabine vs SAQ and ZDV vs ddC and ZDV. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35: 236, 1995

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. New England Journal of Medicine 334(16): 1011-1017, 1996

Extreme suppression of HIV-1 plasma RNA using a combination of zidovudine, didanosine, zalcitabine, epivir, saquinavir, and interferon-alpha in subjects with HIV-1 infection. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS [Author] Eleventh International Conference on AIDS, Vol Two One world: One hope : 78, 1996

Randomised, multicentre phase III study of saquinavir plus zidovudine plus zalcitabine in previously untreated or minimally pretreated HIV-infected patients. Clinical Drug Investigation 20(5): 295-307, 2000